Pharmaceutical

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today reported financial results for the three and twelve months ended December 31, 2017. As quoted in the press release: “In 2017, Sarepta advanced our ambitious vision to make a profound difference in …

Sarepta Therapeutics (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, today reported financial results for the three and twelve months ended December 31, 2017.

As quoted in the press release:

“In 2017, Sarepta advanced our ambitious vision to make a profound difference in the lives of those with Duchenne muscular dystrophy (DMD) and furthered our position as an important global genetic medicine company in rare disease. We accelerated our industry-leading DMD pipeline composed of some 16 programs across our RNA-targeted, gene therapy and gene-editing platforms; raised substantial resources to invest in our programs; and delivered on our commitment to execute a successful launch for EXONDYS 51, our first genetic medicine therapy for DMD,” said Douglas Ingram, Sarepta’s president and chief executive officer.

Click here to read the full press release.

Featured

MARKETS

Markets
TSX21205.16-69.41
TSXV900.87+10.01
DOW35028.65-339.82
S&P 5004532.76-44.35
NASD14340.26-166.64
ASX7332.50-76.30

COMMODITIES

Commodities
Gold1838.56+0.14
Silver24.20+0.12
Copper4.52+0.05
Palladium2071.50+91.00
Platinum1047.00+30.00
Oil86.79-0.17
Heating Oil2.62-0.02
Natural Gas4.01-0.03

DOWNLOAD FREE REPORTS

×